Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Anne S. Tsao, MD, has no real or apparent conflicts of interest to report.
Associate Scientific Director
Editorial Director, Hematology/Oncology
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is intended for physicians and other healthcare professionals who provide medical care for patients with mesothelioma.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 01, 2016, through June 30, 2017:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
CME-certified Webcast of a CCO symposium at CHEST 2019 featuring expert perspectives on optimal integration of immunotherapy into stage III NSCLC care using a multidisciplinary approach
In this slideset, experts provide insights on immunotherapy use for stage III NSCLC today and emerging developments in this setting and earlier stages of NSCLC.
In this slideset, Sanjay Mukhopadhyay, MD, reviews biomarker testing in lung cancer, including molecular testing by NGS and PD-L1 testing to predict response to checkpoint inhibitors.
In this slideset, Joshua Bauml, MD; Sandip P. Patel, MD; and H. Jack West, MD, review the latest clinical data supporting the optimal use of biomarker testing for checkpoint inhibitor therapy across lung cancer.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.